VCs Supported UK Biotech In 2024’s Tricky Funding Environment

 
• By Andrew McConaghie
  
The UK remains the best capitalized European biotech sector but no IPOs and few licensing deals meant its companies had limited funding options in 2024. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Start-Ups & SMEs